BTIG Research Reiterates “Buy” Rating for Ovid Therapeutics (NASDAQ:OVID)

Ovid Therapeutics (NASDAQ:OVID)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a research note issued to investors on Thursday,Benzinga reports. They presently have a $4.00 target price on the stock. BTIG Research’s target price indicates a potential upside of 73.91% from the company’s current price.

OVID has been the topic of several other reports. Lifesci Capital initiated coverage on Ovid Therapeutics in a research note on Monday, December 22nd. They issued an “outperform” rating and a $4.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ovid Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Ovid Therapeutics in a report on Monday, December 22nd. Wall Street Zen upgraded Ovid Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Wedbush upped their price objective on shares of Ovid Therapeutics from $5.00 to $7.00 and gave the company an “outperform” rating in a report on Friday, March 20th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $4.38.

Ovid Therapeutics Stock Performance

NASDAQ OVID opened at $2.30 on Thursday. The company has a market capitalization of $163.78 million, a PE ratio of -7.42 and a beta of 0.25. The company has a debt-to-equity ratio of 0.09, a quick ratio of 8.97 and a current ratio of 8.97. Ovid Therapeutics has a 52-week low of $0.24 and a 52-week high of $2.72. The company has a 50-day simple moving average of $1.79 and a 200 day simple moving average of $1.61.

Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Wednesday, March 18th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.16. Ovid Therapeutics had a negative net margin of 240.11% and a negative return on equity of 23.98%. The firm had revenue of $0.72 million for the quarter, compared to analysts’ expectations of $0.06 million. On average, research analysts predict that Ovid Therapeutics will post -0.4 EPS for the current year.

Hedge Funds Weigh In On Ovid Therapeutics

A number of large investors have recently made changes to their positions in OVID. Benin Management CORP purchased a new position in shares of Ovid Therapeutics in the fourth quarter valued at $31,000. Private Advisor Group LLC purchased a new stake in Ovid Therapeutics during the 3rd quarter worth about $33,000. Apollon Wealth Management LLC bought a new position in Ovid Therapeutics in the 3rd quarter worth about $36,000. Total Clarity Wealth Management Inc. bought a new position in Ovid Therapeutics in the 4th quarter worth about $47,000. Finally, LPL Financial LLC grew its holdings in Ovid Therapeutics by 150.0% during the 4th quarter. LPL Financial LLC now owns 30,000 shares of the company’s stock valued at $49,000 after buying an additional 18,000 shares in the last quarter. 72.24% of the stock is owned by institutional investors.

More Ovid Therapeutics News

Here are the key news stories impacting Ovid Therapeutics this week:

• Positive Sentiment: Analysts raised the firmwide price target to $4.87 (a 14.29% increase) — a materially higher target that signals stronger upside vs. the current price and may support buying interest. Ovid Therapeutics (OVID) price target increased by 14.29% to 4.87
• Positive Sentiment: BTIG reaffirmed its “Buy” rating and set a $4.00 price target, implying roughly 70%+ upside from current levels — another institutional vote of confidence that can attract momentum buyers. BTIG reaffirmed buy, $4 PT
• Positive Sentiment: Lifesci Capital raised several quarterly EPS forecasts (Q2–Q4 2026 were nudged higher) and reiterated an “Outperform” rating with a $4.00 target — upgrades to near-term estimates and a maintained outperform stance reinforce bullish analyst sentiment. Lifesci Capital research notes on OVID
• Positive Sentiment: Brokerage consensus remains favorable — a recent summary shows a consensus “Buy” rating from covering firms, which tends to support investor confidence. Ovid given consensus ‘Buy’ by brokerages
• Negative Sentiment: Offsetting the upbeat notes, Lifesci trimmed its Q1 2026 EPS forecast (to -$0.11 from -$0.08), which is a nearer‑term earnings disappointment risk and could pressure sentiment if short-term execution concerns persist. Lifesci cut Q1 2026 EPS estimate

Ovid Therapeutics Company Profile

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.